Med Discovery SA

Switzerland's Med Discovery was founded on the discovery of a prostate cancer target, human kallikrein 2, a key protease associated with prostate biology that is thought to contribute to cancer progression and development. The start-up's lead protease inhibitor targets hK2 and is based on the natural serine protease inhibitor ACT, which the company believes will avoid the selectivity and toxicities of other protease inhibitors. Med Discovery is developing the candidate for prostate cancer, but it believes it also has potential for treating skin disorders and for immunological treatment of cancer.